Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study

被引：1
|
作者：
Mohan, K. [1 ]
Prajapati, A. [2 ]
Kothari, R. K. [3 ]
Mondal, S. [4 ]
Nagarkar, R. [5 ]
Kane, S. B. [6 ]
Santa, A. [1 ]
Dadke, D. [7 ]
机构：
[1] Basavatarakam Indo Amer Canc Hosp & Res Inst, Med Oncol, Hyderabad, India
[2] Curateq Biol Private Ltd, Clin Dev, Hyderabad, India
[3] Narayana Multispecialty Hosp, Med Oncol, Ahmadabad, Gujarat, India
[4] Nilratan Sircar Med Coll & Hosp, Radiotherapy, Kolkata, India
[5] HCG Manavata Canc Ctr, Surg Oncol, Nasik, India
[6] RST Reg Canc Ctr, Med Oncol, Nagpur, Maharashtra, India
[7] Curateq Biol Private Ltd, Hyderabad, India
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.201
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
67P
引用
收藏
页码：S1491 / S1491
页数：1
相关论文
共 50 条
  • [31] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
    J. Gavilá
    J. De La Haba
    B. Bermejo
    Á. Rodríguez-Lescure
    A. Antón
    E. Ciruelos
    J. Brunet
    E. Muñoz-Couselo
    M. Santisteban
    C. A. Rodríguez Sánchez
    A. Santaballa
    P. Sánchez Rovira
    J. Á. García Sáenz
    M. Ruiz-Borrego
    A. L. Guerrero-Zotano
    M. Huerta
    A. Cotes-Sanchís
    J. Lao Romera
    E. Aguirre
    J. Cortés
    A. Llombart-Cussac
    Clinical and Translational Oncology, 2020, 22 : 420 - 428
  • [32] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
    Gavila, J.
    De La Haba, J.
    Bermejo, B.
    Rodriguez-Lescure, A.
    Anton, A.
    Ciruelos, E.
    Brunet, J.
    Munoz-Couselo, E.
    Santisteban, M.
    Rodriguez Sanchez, C. A.
    Santaballa, A.
    Sanchez Rovira, P.
    Garcia Saenz, J. a.
    Ruiz-Borrego, M.
    Guerrero-Zotano, A. L.
    Huerta, M.
    Cotes-Sanchis, A.
    Lao Romera, J.
    Aguirre, E.
    Cortes, J.
    Llombart-Cussac, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (03): : 420 - 428
  • [33] Efficacy and safety of trastuzumab biosimilar Abdi Ibrahim in the neoadjuvant setting for HER2 positive breast cancer: about 40 cases
    Neche, N.
    Kouadri, N.
    Djedi, H.
    BREAST, 2023, 68 : S64 - S64
  • [34] Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Osako, Tomo
    Ito, Yoshinori
    Takahashi, Shunji
    Tokudome, Nahomi
    Iwase, Takuji
    Hatake, Kiyohiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (01) : 159 - 164
  • [35] Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience
    Bahceci, Aykut
    Paydas, Semra
    Ak, Naziye
    Ferhatoglu, Ferhat
    Saip, Pinar Mualla
    Seydaoglu, Gulsah
    Bilici, Mehmet
    Simsek, Melih
    Tekin, Salim Basol
    Calikusu, Zuleyha
    Yavuz, Sinan
    Sahin, Ahmet Bilgehan
    Cubukcu, Erdem
    Evrensel, Turkkan
    Degirmencioglu, Serkan
    Demiray, Atike Gokcen
    Yumuk, Perran Fulden
    Alan, Ozkan
    Cikman, Duygu Ilke
    Demirelli, Fuat Hulusi
    Kostek, Osman
    Gokyer, Ali
    Dogan, Mutlu
    Bal, Oznur
    Cakar, Burcu
    Gokmen, Erhan
    Yamac, Deniz
    Korkmaz, Taner
    Aliyev, Altay
    Keskin, Ozge
    Urvay, Semiha
    Buyuksimsek, Mahmut
    Karadeniz, Cemile
    Yildiz, Birol
    Cinkir, Havva Yesil
    Demir, Hacer
    Beypinar, Ismail
    Karacin, Cengiz
    Eser, Kadir
    Baykara, Meltem
    Kilickap, Saadettin
    Okutur, Kerem
    Bulut, Gulcan
    Alkan, Ali
    Arpaci, Erkan
    Pilanci, Kezban Nur
    Demir, Atakan
    Isik, Deniz
    Yildirim, Nilgun
    CANCER INVESTIGATION, 2021, 39 (6-7) : 473 - 481
  • [36] Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Tomo Osako
    Yoshinori Ito
    Shunji Takahashi
    Nahomi Tokudome
    Takuji Iwase
    Kiyohiko Hatake
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 159 - 164
  • [37] Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic HER2-positive breast cancer
    Becherini, Carlotta
    Bertini, Niccolo'
    Bonaparte, Ilaria
    Burchini, Luca
    Orsatti, Carolina
    Valzano, Marianna
    Banini, Marco
    Salvestrini, Viola
    Scoccimarro, Erika
    Scotti, Vieri
    Desideri, Isacco
    Francolini, Giulio
    Orzalesi, Lorenzo
    Bernini, Marco
    Tommasi, Cinzia
    Nori, Jacopo
    Bianchi, Simonetta
    Meattini, Icro
    Livi, Lorenzo
    CANCER RESEARCH, 2024, 84 (09)
  • [38] A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer
    Tolaney, S. M.
    Najita, J.
    Chen, W.
    Savoie, J.
    Fornier, M.
    Krop, I. E.
    Winer, E. P.
    Bunnell, C.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 243S
  • [39] Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort study
    Sawaki, Masataka
    Mukai, Hirofumi
    Tokudome, Nahomi
    Nakayama, Takahiro
    Taira, Naruto
    Mizuno, Toshiro
    Yamamoto, Yutaka
    Horio, Akiyo
    Watanabe, Toru
    Uemura, Yukari
    Ohashi, Yasuo
    BREAST CANCER, 2012, 19 (03) : 253 - 258
  • [40] A PHASE 2 STUDY OF TRASTUZUMAB EMTANSINE IN JAPANESE PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER
    Takahashi, S.
    Kashiwaba, M.
    Takao, S.
    Ito, Y.
    Doihara, H.
    Rai, Y.
    Matsubara, M.
    Kanatani, K.
    Masuda, N.
    ANNALS OF ONCOLOGY, 2013, 24 : 20 - 20
12345